Skip to main content

Advertisement

Table 1 Current and potential future chemotherapeutic options for pancreatic ductal adenocarcinoma

From: Pancreatic cancer genomics: insights and opportunities for clinical translation

Agent Patients targeted Median overall survival References
Mitomycin Ca Patients with mutations in PALB2 - [61]
Olapariba Patients with mutations in BRCA2 - [68, 69]
Gemcitabine alone All 5.65-7.2 monthsb [9, 9094]
Gemcitabine + cisplatin All 7.5 months [91]
Gemcitabine + erlotinib All 6.2 months [10]
Gemcitabine + capecitabine All 7.1-8.4 monthsb [93, 94]
Gemcitabine + docetaxel + capecitabine (GTX)a All - [95]
Gemcitabine + Nab-paclitaxel All 12.2 months [11]
Folinic acid + fluorouracil + irinotecan + oxaliplatin (FOLFIRINOX) All 11.1 months [90]
  1. aThese regimens have shown promise based on preliminary data in pancreatic cancer or in clinical trials in other cancer types.
  2. bIf more than one trial has been reported the range of median overall survivals is listed.